Search
One of The Kids Research Institute Australia’s leading young researchers will travel to the world’s premier conference on childhood brain cancer.
New research by The Kids shows donor immune cells are highly effective at boosting the body’s response against leukaemia.
Researchers at The Kids Research Institute Australia have been awarded $4.6 million in national funding from the National Health and Medical Research Council (NHMRC) and Medical Research Future Fund (MRFF) to help support child health research.
The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.
A The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
Preclinical research from the WA Comprehensive Kids Cancer Centre has revealed a promising new strategy to protect bone health in children with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), showing that actively rebuilding bone may deliver faster and more effective protection against debilitating fractur
Valuable support from the Raine Medical Research Foundation’s 2025 grant round will power four new research projects at The Kids Research Institute Australia.
A landmark study led by Dr Hetal Dholaria, The Kids Research Institute Australia researcher and Perth Children’s Hospital Oncologist, has confirmed that a “wait and watch” approach for newborns diagnosed with neuroblastoma is not only safe, but effective over the long term.
T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.
High-grade gliomas including glioblastoma (GBM) and diffuse midline gliomas (DMG) represent the most lethal and aggressive brain cancers where current treatment modalities offer limited efficacy. Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising strategy, boasting tumor-specific targeting and the unique ability to penetrate the blood-brain barrier.